"This is the first time that a drug has been able to decrease the rate of disease progression in addition to improving a significant proportion of patients with progressive MS," said MedDay CEO Frederic Sedel in a statement.
The experimental MD1003 drug underwent Phase III clinical trial, the last stage before filing for authorization to market the drug in the treatment of primary and secondary progressive multiple sclerosis.
"The rapid rate of recruitment into this multi-centre study illustrates the serious need for a well-tolerated drug by patients with primary and secondary progressive multiple sclerosis," he added in the company's statement.
"The significant proportion of patients showing improvement at twelve months, coupled with the decrease in risk of disease progression demonstrated here, makes MD1003 a potentially important new therapy for patients and clinicians in the field of MS."
The application process to license the drug will begin when all the test results are in, expected by the end of the year.
- » News Central
- » Popular News
- » Latest Health News
- » News Category A-Z (500+)
- » Health News and Press Release
- » News Archive
- » News Photo Gallery
- » Lifestyle and Wellness
- » Health Watch
- » Health In Focus
- » Celebrating Life
- » Breaking Health News
- » News From Other Resources
- » India Special
- » News Video Gallery
- » Medindia Exclusive - Interviews and In depth Reports